Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021)
Recursion Pharmaceuticals' (RXRX) quarterly Preferred Stock Liabilities came in at $448.3 million in Q1 2021, up 122.92% YoY from $201.1 million in Q1 2020, and little changed on a QoQ basis from $448.3 million in Q4 2020.
Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 2 years of Preferred Stock Liabilities data on file, last reported at $448.3 million in Q1 2021.
- Quarterly Preferred Stock Liabilities rose 122.92% year-over-year to $448.3 million in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $448.3 million (up 122.92% YoY) and the FY2020 annual result came in at $448.3 million, up 122.92% from the prior year.
- Preferred Stock Liabilities held at $448.3 million in Q1 2021, from $448.3 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $448.3 million in Q4 2020 to a low of $201.1 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 448.31 Mn |
| Dec 31, 2020 | 448.31 Mn |
| Sep 30, 2020 | 437.92 Mn |
| Jun 30, 2020 | 201.11 Mn |
| Mar 31, 2020 | 201.11 Mn |